Search
Sol Gel Technologies Ltd
SLGLAdd to Watchlist
72.720USD
+4.040+5.88%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
236.00MMarket Cap
LossP/E TTM
More Details of Sol Gel Technologies Ltd Company
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
Sol Gel Technologies Ltd Info
Ticker SymbolSLGL
Company nameSol Gel Technologies Ltd
IPO dateFeb 01, 2018
CEO- -
Number of employees34
Security typeOrdinary Share
Fiscal year-endFeb 01
AddressGolda Meir 7
CityNESS-ZIONA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code- -
Phone97289313433
Websitehttp://www.sol-gel.com
Ticker SymbolSLGL
IPO dateFeb 01, 2018
CEO- -
Company Executives of Sol Gel Technologies Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
1.55K
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--
Dr. Dubi (Dov) Zamir, Ph.D.
Dr. Dubi (Dov) Zamir, Ph.D.
Vice President - Special Projects
Vice President - Special Projects
--
--
Mr. Itai Arkin
Mr. Itai Arkin
Director
Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
1.55K
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, May 9
Updated: Sat, May 9
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
M.Arkin Dermatology, Ltd.
55.68%
Opaleye Management Inc.
14.18%
Great Point Partners, LLC
8.45%
Phoenix Investment and Finances Ltd
6.50%
Arkin (Moshe)
4.41%
Other
10.77%
Shareholders
Shareholders
Proportion
M.Arkin Dermatology, Ltd.
55.68%
Opaleye Management Inc.
14.18%
Great Point Partners, LLC
8.45%
Phoenix Investment and Finances Ltd
6.50%
Arkin (Moshe)
4.41%
Other
10.77%
Shareholder Types
Shareholders
Proportion
Corporation
55.68%
Hedge Fund
22.83%
Investment Advisor
7.62%
Individual Investor
4.46%
Insurance Company
0.23%
Research Firm
0.16%
Investment Advisor/Hedge Fund
0.08%
Other
8.94%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
39
1.00M
30.93%
-175.34K
2025Q4
35
634.85K
22.79%
-440.31K
2025Q3
35
286.02K
10.27%
-480.14K
2025Q2
36
2.50M
89.88%
-104.83K
2025Q1
37
2.45M
84.60%
+78.00K
2024Q4
35
23.50M
84.37%
-314.30K
2024Q3
34
23.55M
84.52%
-115.49K
2024Q2
31
25.52M
91.61%
+1.51M
2024Q1
30
23.87M
85.67%
+1.61M
2023Q4
31
22.12M
83.66%
-222.95K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
M.Arkin Dermatology, Ltd.
1.81M
64.86%
--
--
Jun 11, 2025
Opaleye Management Inc.
383.58K
13.77%
+10.43K
+2.80%
Dec 17, 2025
Phoenix Investment and Finances Ltd
218.22K
7.83%
-28.80K
-11.66%
Sep 30, 2025
Arkin (Moshe)
143.26K
5.14%
+105.12K
+275.67%
Jun 11, 2025
Yelin Lapidot Provident Funds Management Ltd
17.75K
0.55%
+17.75K
--
Dec 31, 2025
Menora Mivtachim Insurance Ltd.
7.61K
0.27%
+7.61K
--
Sep 30, 2025
Citadel Advisors LLC
6.20K
0.19%
+6.20K
--
Dec 31, 2025
Raymond James Financial Services Advisors, Inc.
--
0%
-7.81K
-100.00%
Sep 30, 2025
Morgan Stanley & Co. LLC
4.37K
0.16%
-970.00
-18.18%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
May 01, 2025
Merger
10→1
Date
Ex-dividend Date
Type
Ratio
May 01, 2025
Merger
10→1
